4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 560-568

  De Graan, Anne Joy M ^a   Sparreboom, Alex ^a,c   De Bruijn, Peter ^a   De Jonge, Evert ^b   Van Der Holt, Bronno ^b   Wiemer, Erik A C ^a   Verweij, Jaap ^a   Mathijssen, Ron H J ^a   Van Schaik, Ron H N ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

4 hydroxycholesterol; CYP3A activity; endogenous marker; pharmacokinetics; taxanes

Indexed keywords

4BETA HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A; DOCETAXEL; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHOLEST-5-ENE-3,4-DIOL; CYP3A PROTEIN, HUMAN; TAXOID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS; YOUNG ADULT;

EID: 84940450721     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12707     Document Type: Article

References (42)

1. Choy H,. Combining taxanes with radiation for solid tumors. Int J Cancer 2000; 90: 113-27.
2. Henningsson A, Sparreboom A, Sandström M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO,. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003; 39: 1105-14.
3. Markman M,. Managing taxane toxicities. Support Care Cancer 2003; 11: 144-7.
4. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB,. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96.
5. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR,. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-9.
6. Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH,. Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat Rev 2015; 41: 605-13.
7. Lin JH, Lu AY,. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-90.
8. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV,. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391-401.
9. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM,. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-35.
10. Mathijssen RH, van Schaik RH,. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur J Cancer 2006; 42: 141-8.
11. Benet LZ,. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 2005; 5: 79-83.
12. Kharasch ED, Thummel KE, Watkins PB,. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv 2005; 5: 151-3.
13. Streetman DS, Bertino JS Jr, Nafziger AN,. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
14. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N,. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18: 2301-8.
15. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U,. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem 2001; 276: 38685-9.
16. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalysy U,. Metabolism of 4 beta-hydroxycholesterol in humans. J Biol Chem 2002; 277: 31534-40.
17. Diczfalusy U, Nylen H, Elander P, Bertilsson L,. 4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 2011; 71: 183-9.
18. Yang Z, Rodrigues AD,. Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? J Clin Pharmacol 2010; 50: 1330-8.
19. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L,. 4β-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 2009; 67: 38-43.
20. Mirghani RA, Sayi J, Aklillu E, Allgvist A, Jande M, Wennerholm A, Eriksen J, Herben VM, Jones BC, Gustafsson LL, Bertilsson L,. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics 2006; 16: 637-45.
21. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Savi J, Larsson H, Bodin KG, Allgvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L,. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18: 201-8.
22. Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH,. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006; 12: 2150-7.
23. de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH,. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res 2012; 18: 4425-32.
24. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A,. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012; 18: 4433-40.
25. Alexander SP, Mathie A, Peters JA,. Guide to receptors and channels (GRAC), 5th edition (2011). Br J Pharmacol 2011; 164 (Suppl. 1): S1-S324.
26. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A,. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 693: 437-41.
27. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J,. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006; 5: 833-9.
28. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A,. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem 2004; 324: 276-84.
29. Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J,. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 705: 159-64.
30. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB,. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72.
31. Henningsson A,. Population Pharmacokinetic Model for Cremophor EL Annual meeting of the Population Approach Group in Europe 2005.
32. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G,. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-7.
33. Yamashita K, Kobayashi S, Tsukamoto S, Numazawa M,. Synthesis of pyridine-carboxylate derivatives of hydroxysteroids for liquid chromatography-electrospray ionization-mass spectrometry. Steroids 2007; 72: 50-9.
34. Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U,. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther 2009; 86: 147-53.
35. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC,. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011; 127: 153-62.
36. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM,. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-56.
37. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA,. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
38. Backman JT, Olkkola KT, Neuvonen PJ,. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
39. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH,. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8.
40. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N,. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005; 23: 1061-9.
41. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A,. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004; 96: 1585-92.
42. Michael M, Cullinane C, Hatzimihalis A, O'Kane C, Milner A, Booth R, Schlicht S, Clarke SJ, Francis P,. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemother Pharmacol 2012; 69: 125-35.